此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium (LaMB)

2015年4月14日 更新者：Queen Mary University of London

A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB]

RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether lapatinib ditosylate is more effective than a placebo in killing tumor cells.

PURPOSE: This randomized phase II/III trial is studying how well lapatinib ditosylate works compared to a placebo in treating patients with stage IV bladder cancer.

研究概览

地位

未知

条件

干预/治疗

详细说明

OBJECTIVES:

Primary

  • Compare progression-free survival in patients with HER1- and/or HER2-overexpressing stage IV bladder cancer who have been randomized to maintenance therapy with lapatinib ditosylate or placebo following first-line chemotherapy.

Secondary

  • Compare overall survival between these patient groups.
  • Evaluate the safety and tolerability of the regimens in these patients.
  • Assess and compare quality of life between these patient groups.

OUTLINE: This is a multicenter study. Patients are stratified according to ECOG performance status and response to first line chemotherapy (complete or partial response vs stable disease). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.

Patients undergo quality of life assessment by EORTC QLQ-C30 at baseline and every 4 weeks during study treatment.

After completion of study treatment, patients are followed up periodically for up to 5 years.

研究类型

介入性

注册 (预期的)

204

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 英国
      • Aberdeen、英国
        • NHS Grampian - Aberdeen Royal Infirmary
      • Basildon、英国
        • Basildon and Thurrock University Hospital NHS Trust - Basildon Hospital
      • Birmingham、英国
        • University Hospitals Birmingham NHS Foundation Trust - Birmingham University Hospital
      • Bournemouth、英国
        • Royal Bournemouth and Christchurch NHS Foundation Trust - Royal Bournemouth Hospital
      • Bristol、英国
        • University Hospitals Bristol NHS Trust - Bristol University Hospital
      • Cambridge、英国
        • Cambridge University Hospitals NHS Trust - Addenbrooke's Hospital
      • Chelmsford、英国
        • Mid Essex NHS Trust - Broomfield Hospital
      • Colchester、英国
        • Colchester University Hospitals NHS Trust
      • Coventry、英国
        • University Hospitals Coventry & Warwickshire NHS Trust
      • Derby、英国
        • Derby Hospitals NHS Trust - Royal Derby Hospital
      • Glasgow、英国
        • NHS Greater Glasgow and Clyde - The Beatson
      • Huddersfield、英国
        • Calderdale and Huddersfield NHS Trust - Huddersfield Royal Infirmary
      • Ipswich、英国
        • Ipswich Hospital NHS Trust
      • Leicester、英国
        • University Hospitals of Leicester NHS Trust
      • Liverpool、英国
        • Clatterbridge Centre for Oncology NHS Trust
      • London、英国
        • Imperial Healthcare NHS Trust
      • London、英国
        • Guys & St Thomas' Hospital NHS Trust - Guys Hospital
      • London、英国
        • Royal Marsden NHS Trust
      • Middlesborough、英国
        • South Tees NHS Trust - James Cook University Hospital
      • Newcastle、英国
        • Newcastle Upon Tyne Hospitals NHS Trust
      • Northampton、英国
        • Northampton General Hospitals NHS Trust
      • Nottingham、英国
        • Nottingham University Hospitals NHS Trust
      • Nottingham、英国
        • Sherwood Forest Hospitals NHS Trust - Kings Mill Hospital
      • Portsmouth、英国
        • Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital
      • Romford、英国
        • Barking, Havering and Redbridge NHS Trust - Queens Hospital
      • Taunton、英国
        • Taunton and Somerset NHS Trust - Musgrove Park Hospital
    • England
      • London、England、英国、EC1M 6BQ
        • Barts and the London NHS Trust

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

DISEASE CHARACTERISTICS:

  • Histologically confirmed transitional cell carcinoma of the bladder

    • Stage IV disease
    • Metastatic or locally advanced disease

  • HER1- and/or HER2-positive disease, defined by the following criteria:

    • 2+ or 3+ intensity on IHC
  • Able to commence the study treatment within 10 weeks of completing chemotherapy

  • Must have achieved objective response or stable disease following 4-8 courses of first-line chemotherapy

    • No progression with first-line chemotherapy for metastatic disease
    • Any widely accepted chemotherapy regimen for bladder cancer allowed
    • Patients who did not receive cisplatin are eligible

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-3
  • ANC ≥ 1.0 x 10^9/L
  • Hemoglobin ≥ 8.0 g/dL
  • Platelet count ≥ 75 x 10^9/L
  • ALT/AST < 2 times upper limit of normal (ULN)
  • Bilirubin < 1.5 times ULN
  • Serum creatinine ≤ 3.0 ULN AND/OR creatinine clearance ≥ 30 mL/min
  • LVEF ≥ 50% (as assessed by quantitative echocardiogram or MUGA)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

  • No current active hepatic or biliary disease, except for any of the following:

    • Gilbert's syndrome
    • Asymptomatic gallstones
    • Liver metastases
    • Stable chronic liver disease per investigator assessment
  • No known hypersensitivity to the study medication

  • No history of prior or concurrent other neoplasms, except for:

    • Any non life-threatening tumours that have been curatively treated.
    • Prostate cancer isolated to the prostate gland

  • No significant cardiac disease, including any of the following:

    • Angina pectoris
    • Severe cardiac arrhythmia requiring medication
    • Severe conduction abnormalities
    • Clinically significant valvular disease
    • Cardiomegaly
    • Prior myocardial infarction
    • Ventricular hypertrophy
    • Congestive heart failure
    • Poorly uncontrolled hypertension (resting diastolic blood pressure > 115 mm Hg)
    • Other cardiomyopathy
  • No serious intercurrent medical or psychiatric illness
  • No serious active infection

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No more than 1 line of prior chemotherapy for metastatic or locally advanced disease (neoadjuvant/adjuvant chemotherapy allowed)
  • No more than 10 weeks since first-line chemotherapy
  • No prior lapatinib ditosylate
  • No prior radiotherapy to the indicator lesion(s) (newly arising lesions in previously irradiated areas allowed)

  • At least 14 days since prior and no concurrent CYP3A4 inducers, including but not limited to, any of the following:

    • Antibiotics (all rifamycin class agents [e.g., rifampicin, rifabutin, rifapentine])
    • Anticonvulsants (phenytoin, carbamazepine, barbiturates [e.g., phenobarbital])
    • Oral glucocorticoids (cortisone [> 50 mg], hydrocortisone [> 40 mg], prednisone [> 10 mg], methylprednisolone [> 8 mg], dexamethasone [> 2 mg²])
    • St. John's wort or modafinil

  • At least 7 days since prior and no concurrent CYP3A4 inhibitors, including but not limited to, any of the following:

    • Antibiotics (clarithromycin, erythromycin, troleandomycin)
    • Antifungals (itraconazole, ketoconazole, fluconazole [>150 mg daily], voriconazole)
    • Antiretrovirals/protease inhibitors (delavirdine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, lopinavir)
    • Calcium channel blockers (verapamil, diltiazem)
    • Antidepressants (nefazodone, fluvoxamine)
    • Gastrointestinal agents (cimetidine, aprepitant)
    • Grapefruit, grapefruit juice
  • At least 6 months since prior and no concurrent amiodarone
  • No concurrent radical or curative therapy (radiotherapy or surgery) at the end of first-line treatment (palliative radiotherapy allowed)
  • No other concurrent experimental or investigational drugs
  • No other concurrent anticancer treatment, including cytotoxic or specific immune therapy

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的：Arm I
Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
药品：拉帕替尼二甲苯磺酸盐
口头给予
其他名称：
  • 泰克布
  • 副词
安慰剂比较：Arm II
Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
其他：安慰剂
口头给予

研究衡量的是什么？

主要结果指标

结果测量
大体时间
Progression free survival
大体时间：Disease Progression - at least 20% increase in the sum of longest diameters of target lesions.
Disease Progression - at least 20% increase in the sum of longest diameters of target lesions.

次要结果测量

结果测量
总生存期

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Queen Mary University of London

合作者

GlaxoSmithKline

调查人员

  • 首席研究员：Thomas Powles, MD, MRCP、Queen Mary University of London

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年3月1日

初级完成 (预期的)

2015年7月1日

研究注册日期

首次提交

2009年7月29日

首先提交符合 QC 标准的

2009年7月29日

首次发布 (估计)

2009年7月30日

研究记录更新

最后更新发布 (估计)

2015年4月15日

上次提交的符合 QC 标准的更新

2015年4月14日

最后验证

2015年4月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CDR0000640393
  • OCTG-LaMB
  • BL-2007-02
  • EUDRACT-2007-001826-28
  • EU-20929

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅